ArticleJAMA network open2020
Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US.
Article in JAMA network open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Racial and ethnic differences in valuation of life expectancy in prostate cancer treatment decision making.Prostate cancer and prostatic diseases · 2026Article
- Association of Socioeconomic Position, Prostate-specific Antigen, and Age with Observation in Low-risk Prostate Cancer Patients in Switzerland.European urology open science · 2026Article
- Treatment variations in localised prostate cancer in Australia and New Zealand: a registry study.BJU international · 2025Article
- Article
- The association of patient and disease characteristics with the overtreatment of low-risk prostate cancer from 2010 to 2016.Prostate cancer and prostatic diseases · 2025Article
- Is uptake of AS in low-risk prostate cancer in Ontario linked to guideline publication?Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Article
- The burden of prostate cancer in the North Africa and Middle East Region from 1990 to 2021.Scientific reports · 2025Article
- Physician Payment Incentives and Active Surveillance in Low-Risk Prostate Cancer.JAMA network open · 2025Article
- Exploration of social determinants of health and prostate cancer prevalence in the US: a cross-sectional study of NHANES data from 2003 to 2010.Frontiers in public health · 2025Article
- County-level racial disparities in prostate cancer-specific mortality from 2005 to 2020.JNCI cancer spectrum · 2024Article
- Genomics in active surveillance and post-prostatectomy patients: A review of when and how to use effectively.Current urology reports · 2024Review
- Racial and Ethnic Variation in Receipt and Intensity of Active Surveillance for Older Patients With Localized Prostate Cancer.Urology practice · 2024Article
- Article
- Patient and physician perspectives on treatments for low-risk prostate cancer: a qualitative study.BMC cancer · 2023Article
- Observation, Radiotherapy, or Radical Prostatectomy for Localized Prostate Cancer: Survival Analysis in the United States.The world journal of men's health · 2023Article
- Active surveillance should be considered for select men with Grade Group 2 prostate cancer.BMC urology · 2023Review
- Racial disparities in cancer care, an eyeopener for developing better global cancer management strategies.Cancer reports (Hoboken, N.J.) · 2023Review
- Explainable ML models for a deeper insight on treatment decision for localized prostate cancer.Scientific reports · 2023Article
- Use of expectant management based on prostate cancer risk and health status: How far are we from a risk-adapted approach?Urologic oncology · 2023Article
- Variations in the Uptake of Active Surveillance for Prostate Cancer and Its Impact on Outcomes.European urology open science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Active surveillance (AS) is now recognized as the preferred management option for most low-risk prostate cancers to minimize risks of overtreatment. Despite increasing use of AS in the US, wide regional variability has been observed, and these regional variations in contemporary practice have not been well described. Objective: To explore variations between county and Surveillance, Epidemiology, and End Results (SEER) regions in AS in the US. Design, Setting, and Participants: A cohort study using the SEER Prostate with Watchful Waiting (WW) database linked to the County Area Health Resource File for detailed county-level demographics and physician distribution data was conducted from January 2010 to December 2015. Analysis was performed in October 2020. A total of 79 825 men with clinically localized, low-risk prostate cancer eligible for AS or WW were included. Exposures: Multiple patient-, county-, and SEER region-level factors, including age, year of diagnosis, county-level densities of urologists, radiation oncologists, primary care physicians, and SEER registry region. Main Outcomes and Measures: Use of AS or WW as the initial reported treatment strategy were noted. Hierarchical mixed-effect logistic regression models were used to evaluate clustered random regional variation on use of AS or WW. Temporal trends by year in proportions of initial treatment type, as well as county-level local variation, were also estimated. Results: Of 79 825 men (mean [SD] age, 62.8 [7.6] years, 11 292 [14.1%] non-Hispanic Black, 7506 [9.4%] Hispanic) with low-risk prostate cancer, the mean annualized percent increase in AS rates from 2010 to 2015 ranged from 6.3% in New Mexico to 81.0% in New Jersey. Differences across SEER regions accounted for 17% of the total variation in AS. Increasing age (51-60 years: odds ratio [OR], 1.33; 95% CI, 1.21-1.46; 61-70 years: OR, 1.86; 95% CI, 1.70-2.04; 71-80 years: OR, 2.26; 95% CI, 2.05-2.50) was associated with greater odds of AS. Hispanic ethnicity (OR, 0.79; 95% CI, 0.74-0.85), T category (OR, 0.79; 95% CI, 0.73-0.84), and Medicaid enrollment (OR, 0.73; 95% CI, 0.66-0.81) were associated with lower odds of AS. Black race, county-level socioeconomic factors (household income, educational level, and city type), and specialist densities were not associated with AS use. Conclusions and Relevance: In this US cohort study based on the SEER-WW database, although the use of AS increased, considerable practice variation appeared to be associated with geographic location, but use of AS was not associated with Black race, specialty professional density, or socioeconomic factors. This small area variation underlies the broader national trends in AS practice and may inform policies aimed at continuing to affect risk-appropriate care for men throughout the US.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.